1026630-32-9

Basic information

• Product Name: 4-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-hydroxy-7-(tetrahydro-pyran-2-yl)-3,4-dihydro-2H,7H-pyridazino[4,5-b][1,4]oxazin-8-one
• Synonyms: 4-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-hydroxy-7-(tetrahydro-pyran-2-yl)-3,4-dihydro-2H,7H-pyridazino[4,5-b][1,4]oxazin-8-one
• CAS NO: 1026630-32-9
• Molecular Weight: 417.462
• Mol File: 1026630-32-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-hydroxy-7-(tetrahydro-pyran-2-yl)-3,4-dihydro-2H,7H-pyridazino[4,5-b][1,4]oxazin-8-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-hydroxy-7-(tetrahydro-pyran-2-yl)-3,4-dihydro-2H,7H-pyridazino[4,5-b][1,4]oxazin-8-one(1026630-32-9)
• EPA Substance Registry System: 4-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-hydroxy-7-(tetrahydro-pyran-2-yl)-3,4-dihydro-2H,7H-pyridazino[4,5-b][1,4]oxazin-8-one(1026630-32-9)

Safety Data

• Hazardous Substances Data: 1026630-32-9(Hazardous Substances Data)

Upstream product

• 645405-18-1 4-chloro-5-hydroxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 110-87-2 3,4-dihydro-2H-pyran 
• 645405-25-0 4-(3,4-dimethoxyphenethyl)-7-(tetrahydro-2H-pyran-2-yl)-2H-pyridazino[4,5-b][1,4]oxazine-3,8(4H,7H)-dione 
• 173206-12-7 4-chloro-5-methoxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 173206-13-8 4,5-dichloro-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 

Relevant articles and documents

Synthetic studies on isoquinoline derivatives with multidrug resistance (MDR) modulating activity

Tetrahydropyridazino-1,4-oxazinoisoquinoline derivatives with multidrug Resist. (MDR) modulating activity were designed and synthesized. A key step for cyclization of 1,4-oxazine ring was developed using K2CO3 and CH3CN in one-pot. Among prepared compounds, 2-(4-fluorobenzyl)-9,10-dimethoxy-12-methyl-6,7,11b,12-tetrahydropyridazino[4', 5',5,6] [1,4]oxazine-[3,4,-a]isoquinolin-1(2H)-one (1f) exhibited significant MDR reversing activity and low toxicity, which might be as potential MDR agent.